Sign in

    Philip Coover

    Research Analyst at Goldman Sachs

    Philip Coover is an Equity Analyst at Goldman Sachs specializing in coverage of medical device companies, particularly Establishment Labs Holdings (ESTA). His analyst ratings have demonstrated a strong performance track record with individual calls on ESTA generating returns ranging from -34.08% to 157.09% over various periods, highlighting his ability to recognize both upward and downward stock movements. Coover began his career less than a year ago and previously held roles at Citigroup, Bertner Advisors, and two other firms before joining Goldman Sachs. He holds professional credentials relevant to equity analysis, although specific securities licenses and FINRA registration details are not publicly disclosed.

    Philip Coover's questions to Beta Bionics (BBNX) leadership

    Philip Coover's questions to Beta Bionics (BBNX) leadership • Q2 2025

    Question

    Philip Coover from Goldman Sachs inquired about the market dynamics driving strong off-label Type 2 patient starts and asked if the growing recurring revenue base improves forecast visibility.

    Answer

    CEO Sean Saint cautiously addressed the Type 2 question, emphasizing that physicians have the discretion to prescribe off-label as they see fit, without detailing specific drivers for Islet. CFO Stephen Feider confirmed that the growing installed base of recurring pharmacy revenue does indeed make the business more predictable and improves visibility into future revenue, even with flat new patient starts.

    Ask Fintool Equity Research AI

    Philip Coover's questions to TANDEM DIABETES CARE (TNDM) leadership

    Philip Coover's questions to TANDEM DIABETES CARE (TNDM) leadership • Q4 2024

    Question

    Philip Coover from Goldman Sachs questioned the OUS business outlook, noting that the 2025 guidance implies a slowdown in year-over-year growth, even after adjusting for the planned transition to direct sales and prior year one-time items.

    Answer

    Leigh Vosseller, Executive Vice President and Chief Financial Officer, acknowledged the various factors affecting the OUS business. She confirmed the 2025 guidance anticipates disruption from the transition to direct sales in select European countries ahead of a 2026 launch. She reiterated that outside of this disruption, the company feels strongly about the long-term growth opportunity in these underpenetrated markets.

    Ask Fintool Equity Research AI